| PRECLINICAL | evidence | GLP-1 receptor agonists and post-endovascular thrombectomy outcomes in acute ischemic stroke: a multicenter propensity score matched analysis. | Semaglutide | — | 2026-09-01 |
| PRECLINICAL | evidence | Depressed mood and suicidal thoughts reporting with GLP-1 receptor agonists in type 2 diabetes: A WHO VigiBase study. | Semaglutide | Glycemic control | 2026-08-15 |
| PRECLINICAL | evidence | Semaglutide and major adverse cardiovascular events in patients with and without DM: A systematic review and meta-analysis. | Semaglutide | — | 2026-08-01 |
| PRECLINICAL | evidence | Association Between Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review. | Semaglutide | Glycemic control | 2026-08-01 |
| PRECLINICAL | evidence | Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Outcomes in Patients With Atherosclerotic Cardiovascular Disease and Obesity Without Diabetes. | Semaglutide | — | 2026-08-01 |
| PRECLINICAL | evidence | Glucagon-like peptide-1 receptor agonists for weight loss in end-stage heart failure patients considered for heart transplantation. | Semaglutide | — | 2026-08-01 |
| PRECLINICAL | evidence | Lifetime cost-effectiveness of semaglutide for secondary prevention in atherosclerotic cardiovascular disease: A select-based simulation study. | Semaglutide | — | 2026-08-01 |
| PRECLINICAL | evidence | GLP-1 receptor agonists in pediatric obesity and diabetes: a systematic review of efficacy, metabolic effects, and safety. | Semaglutide | Glycemic control · n = 901 | 2026-08-01 |
| PRECLINICAL | evidence | Tirzepatide Versus Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes With Established Cardiovascular Disease: An Indirect Treatment Comparison Meta-Analysis. | Semaglutide | — | 2026-08-01 |
| PRECLINICAL | evidence | Effects of Glucagon-Like Peptide-1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review. | Semaglutide | Weight & fat loss | 2026-08-01 |
| PRECLINICAL | evidence | Correction to: "Atypical retrobulbar optic neuropathy after semaglutide escalation". | Semaglutide | — | 2026-08-01 |
| PRECLINICAL | evidence | Correction to 'Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis'. | Semaglutide | — | 2026-08-01 |
| PRECLINICAL | evidence | Dynamics of Body Composition and Metabolic Risk in Adolescents With Obesity Under GLP-1 Receptor Agonist Therapy. | Semaglutide | — | 2026-08-01 |
| PRECLINICAL | evidence | Gestational Weight Gain and Pregnancy Outcomes After Semaglutide Exposure. | Semaglutide | — | 2026-08-01 |
| PRECLINICAL | evidence | Beyond weight loss: multisystem benefits of obesity medications. | Semaglutide | Weight & fat loss | 2026-08-01 |
| PRECLINICAL | evidence | Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials. | Semaglutide | — | 2026-08-01 |
| PRECLINICAL | evidence | Weight Management With Semaglutide and Tirzepatide in U.S. Adults: Projected Impact on Obesity Prevalence and Heart Failure Risk. | Semaglutide | — | 2026-08-01 |
| PRECLINICAL | evidence | Therapeutic Benefit or Ocular Risk? Semaglutide and Non-Arteritic Anterior Ischemic Optic Neuropathy: Retraction. | Semaglutide | — | 2026-08-01 |
| PRECLINICAL | evidence | The Impact of GLP-1-Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta-Analysis. | Semaglutide | Glycemic control | 2026-08-01 |
| PRECLINICAL | evidence | Plain language summary: the evoke(+) studies of semaglutide for early Alzheimer's disease. | Semaglutide | — | 2026-08-01 |
| PRECLINICAL | evidence | 18 F-FDG PET/CT Five Days Post First Administration of Semaglutide : Side Effects in One Shot. | Ozempic | — | 2026-08-01 |
| PRECLINICAL | evidence | Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison. | Semaglutide | Weight & fat loss | 2026-08-01 |
| PRECLINICAL | evidence | Weight Loss Medications in Youth: Decision-Making Experiences, Eating Behaviors, and Uncertainty About Endpoint. | Semaglutide | Weight & fat loss | 2026-08-01 |
| PRECLINICAL | evidence | Semaglutide in Adolescents Living With Obesity: A Real-World Data Study Exploring Predictors of Treatment Response. | Semaglutide | — | 2026-08-01 |
| PRECLINICAL | evidence | Dulaglutide-associated body odor with dechallenge and rechallenge in a patient with type 2 diabetes. | Semaglutide | Glycemic control | 2026-08-01 |
| PRECLINICAL | evidence | Rates of, Reasons for, and Reactions to Discontinuation of GLP-1 Receptor Agonists: A Narrative Review. | Semaglutide | Glycemic control | 2026-08-01 |
| PRECLINICAL | evidence | A Systematic Review and Meta-Analysis of Semaglutide Effects on Adipose Tissue and Emerging Effects on Brain and Cognition. | Semaglutide | Weight & fat loss | 2026-08-01 |
| PRECLINICAL | evidence | Cagrilintide-semaglutide: a new option for patients with type 2 diabetes. | Semaglutide | — | 2026-08-01 |
| PRECLINICAL | evidence | Personalization of incretin therapy: can GLP-1 and GIP receptor polymorphisms influence therapy response? | Semaglutide | — | 2026-08-01 |
| PRECLINICAL | evidence | Risk of Age-Related Ocular Diseases in Non-Diabetic Adults With Obesity Using Glucagon-Like Peptide 1 Receptor Agonists. | Semaglutide | Weight & fat loss | 2026-08-01 |
| PRECLINICAL | evidence | Optic Ischaemic Neuropathy in Incretin-Based Therapy: A Comparative Analysis of Real-World Safety Data. | Semaglutide | Glycemic control | 2026-08-01 |
| PRECLINICAL | evidence | Association of Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review. | Semaglutide | Glycemic control | 2026-08-01 |
| PRECLINICAL | evidence | GLP-1 receptor agonist adjunct therapy stabilises Ramadan dysglycaemia in insulin-treated diabetes: a CGM-based study. | Semaglutide | Glycemic control | 2026-08-01 |
| PRECLINICAL | evidence | Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement by the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology. | Semaglutide | Glycemic control | 2026-08-01 |
| PRECLINICAL | evidence | Evidence-informed guidance for the clinical use of oral semaglutide in obesity management. | Semaglutide | Weight & fat loss | 2026-08-01 |
| PRECLINICAL | evidence | Real-World Effectiveness and 12-Month Persistence of a Semaglutide-Supported Digital Weight-Loss Service: A Retrospective Cohort Study in Germany. | Semaglutide | Weight & fat loss | 2026-08-01 |
| PRECLINICAL | evidence | Comparative Effectiveness and Safety of Once-Weekly Injectable Semaglutide Versus Dulaglutide in Individuals with Type 2 Diabetes Managed in UK Primary Care: A Population-Based Cohort Study. | Semaglutide | — | 2026-08-01 |
| PRECLINICAL | evidence | Prolonged Dysesthesia After Massive Accidental Semaglutide Overdose: A Case Report. | Semaglutide | — | 2026-08-01 |
| PRECLINICAL | evidence | Weight-Lowering Drugs and Natural Female Fertility-A Systematic Review and Meta-Analysis. | Semaglutide | Weight & fat loss | 2026-08-01 |
| PRECLINICAL | evidence | 1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study. | Semaglutide | Glycemic control | 2026-08-01 |
| PRECLINICAL | evidence | Semaglutide and Other GLP-1 Agonists for Antipsychotic-Associated Metabolic Dysfunction in Schizophrenia: A Systematic Review and Meta-Analysis. | Semaglutide | — | 2026-07-27 |
| PRECLINICAL | evidence | Understanding Biased Signaling and Small-Molecule Binding for Treatment of Type 2 Diabetes Mellitus and Obesity at the Glucagon-Like Peptide-1 Receptor (GLP-1R) Based on Molecular Dynamics Simulations. | Semaglutide | — | 2026-07-27 |
| PRECLINICAL | evidence | Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1. | Semaglutide | — | 2026-07-26 |
| PRECLINICAL | evidence | A Cost-Effectiveness Model of Semaglutide 2.4 mg, Resmetirom 80 mg, and Resmetirom 100 mg Versus Standard of Care for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis in the United States. | Semaglutide | — | 2026-07-26 |
| PRECLINICAL | evidence | Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE). | Semaglutide | — | 2026-07-26 |
| PRECLINICAL | evidence | Nutritional intake changes during GLP-1 receptor agonist therapy: A systematic review and meta-analysis. | Semaglutide | — | 2026-07-25 |
| PRECLINICAL | evidence | Therapeutic role of semaglutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis of placebo-controlled trials with GRADE evidence assessment. | Semaglutide | Liver health | 2026-07-24 |
| PRECLINICAL | evidence | Effects of glucagon-like peptide-1 receptor agonists on metabolic outcomes in antipsychotic-treated patients with schizophrenia: A systematic review and meta-analysis. | Semaglutide | — | 2026-07-24 |
| PRECLINICAL | evidence | Semaglutide for prevention of type 2 diabetes in women with postpartum prediabetes after gestational diabetes: protocol for a Belgian multicentre double-blind randomised placebo-controlled trial. | Semaglutide | Glycemic control | 2026-07-23 |
| PRECLINICAL | evidence | Advances in proteomics research related to semaglutide: evidence from humans and animals. | Semaglutide | — | 2026-07-23 |